Select Publications | Research To Practice

Submitted by web@researchtop... on Wed, 05/15/2013 - 11:29

Keynote

Bruce E Johnson, MD

Koivunen JP et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14(13):4275-83. Abstract

Kwak EL et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703. Abstract

McDermott U et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Research 2008;68(9):3389-95. Abstract

Schiller JH et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8. Abstract

Sequist LV et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22(12):2616-24. Abstract

Shaw AT et al. PROFILE 1007: Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in advanced ALK-positive NSCLC. Proc ESMO 2012. No abstract available

Soda M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6. Abstract

Tracy S et al. Gefitinib induces apoptosis in the EGFRL858R non-small cell lung cancer cell line H3255. Cancer Research 2004;64:7241. Abstract

Mutations and Genomic Alterations in Non-Small Cell Lung Cancer (NSCLC)

Thomas J Lynch Jr, MD

Li AR et al. EGFR mutations in lung adenocarcinomas: Clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008;10(3):242-8. Abstract

Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. Abstract

Rosell R et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. Proc ASCO 2011;Abstract 7503.

Yang JCH et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Proc ASCO 2012;Abstract LBA7500.

Bruce E Johnson, MD

Arcila ME et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17(5):1169-80. Abstract

Bergethon K et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30(8):863-70. Abstract

Camidge DR et al. Activity and safety of crizotinib in patients with ALK-positive non-small cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012;13(10):1011-9. Abstract

Kim DW et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Proc ASCO 2012;Abstract 7533.

Ohashi K et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA. 2012;109(31):E2127-33. Abstract

Rimkunas VM et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion. Clin Cancer Res 2012;18(16):4449-57. Abstract

Sequist LV et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3(75):75ra26. Abstract

Shaw AT et al. PROFILE 1007: Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in advanced ALK-positive NSCLC. Proc ESMO 2012. No abstract available

Takeuchi K et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18(3):378-81. Abstract

Zhou W et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462(7276):1070-4. Abstract

Jyoti D Patel, MD

Blumenschein GR et al. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 2012;30:3287-96. Abstract

Sequist LV et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29(24):3307-15. Abstract

Spigel DR et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Proc ASCO 2011;Abstract 7505.

Systemic Management of Pan-Wild-Type (PWT) Metastatic NSCLC

Jyoti D Patel, MD

Barlesi F et al. Final efficacy outcomes for patients with advanced nonsquamous nonsmall cell lung cancer randomized to continuation maintenance with bevacizumab or bevacizumab plus pemetrexed after first-line bevacizumab-cisplatin-pemetrexed treatment. ECCO-ESMO 2011;Abstract LBA34.

Patel J et al. A randomized, open-label, Phase 3, superiority study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (Pts) with stage IIIB or IV non-squamous nonsmall cell lung cancer (Ns-Nsclc). Chicago Multidisciplinary Symposium in Thoracic Oncology 2012;Abstract LBPL1.

Patel JD et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27(20):3284-9. Abstract

Paz-Ares L et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13(3):247-55. Abstract

Paz-Ares L et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). Proc ASCO 2012;Abstract LBA7507.

Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract

Scagliotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51. Abstract

Schiller JH et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8. Abstract

Ramaswamy Govindan, MD

Brahmer JR et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). Proc ASCO 2012;Abstract 7509.

Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25. Abstract

Hanna N et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: The Hoosier Oncology Group and US Oncology. J Clin Oncol 2008;26:5755-60. Abstract

Roychowdhury S et al. Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci Transl Med 2011;3(111):111ra121. Abstract

Schiller JH et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8. Abstract

Winton T et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer. N Engl J Med 2005;352(25):2589-97. Abstract

Mark A Socinski, MD

Renschler MF et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. Chicago Multidisciplinary Symposium in Thoracic Oncology 2012;Poster 110.

Socinski MA et al. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small cell lung cancer. Chicago Multidisciplinary Symposium in Thoracic Oncology 2012;Poster 109.

Socinski MA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 2012;30(17):2055-62. Abstract

Thomas J Lynch Jr, MD

Cappuzzo F et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27(10):1667-74. Abstract

Ding L et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455(7216):1068-75. Abstract

Janjigian YY. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. Proc ESMO 2012. No abstract available

Janjigian YY et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011;17(8):2521-7. Abstract

Miller VA et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 2012;13(5):528-38. Abstract

Neal JW et al. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol 2010;5(11):1855-8. Abstract

Oxnard GR et al. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res 2011;17(19):6322-8. Abstract

Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12(12):3657-60. Abstract

Regales L et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119(10):3000-10. Abstract

Spigel DR et al. The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). Proc ASCO 2012;Abstract TPS7616.

Ongoing Clinical Trials Review

Pirker R et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13(1):33-42. Abstract

Socinski MA et al. Limited-stage small-cell lung cancer: The current status of combined-modality therapy. J Clin Oncol 2007;25(26):4137-45. Abstract

Spigel DR et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Proc ASCO 2011;Abstract 7505.

Current Controversies in the Multidisciplinary Management of Lung Cancer

David R Spigel, MD

Arriagada R et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28(1):35-42. Abstract

Arriagada R et al; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350(4):351-60. Abstract

Goss GD et al. A Phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor inhibitor gefitinib in completely resected Stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. Proc ASCO 2010;Abstract LBA7005.

Kelly K et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 2008;26(15):2450-6. Abstract

Kreuter M et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: The TREAT study. Ann Oncol 2013;24(4):986-92. Abstract

Kreuter M et al. Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT. Proc ASCO 2011;Abstract 7002.

Neal JW et al. The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Proc ASCO 2012;Abstract 7010.

Non-Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small cell lung cancer: Two meta-analyses of individual patient data. Lancet 2010;375(9722):1267-77. Abstract

Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311(7010):899-909. Abstract

Pignon JP et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26(21):3552-9. Abstract

Scagliotti GV et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95(19):1453-61. Abstract

Frank C Detterbeck, MD

Cattaneo SM et al. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg 2008;65(1):231-5. Abstract

Gelman R et al. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 1990;8(3):548-55. Abstract

Jeffrey Bradley, MD

Bradley JD et al. Randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 GY) conformal chemoradiotherapy with or without cetuximab for stage IIIA/IIIB non-small cell lung cancer: Preliminary findings on radiation dose in RTOG 0617. Proc ASTRO 2011;Abstract LBA2.

Kong FS et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer. J Clin Oncol 2007;25(21):3116-23. Abstract

Suntharalingam M et al. Radiation Therapy Oncology Group protocol 02-29: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 2012;84(2):456-63. Abstract

Rogerio C Lilenbaum, MD

Corre R et al. Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a “classical” strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an “optimized” strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary. Proc ASCO 2011;Abstract TPS219.

Davidoff AJ et al. Chemotherapy and survival benefit in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2010;28:2191-7. Abstract

Hurria A et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 2011:3457-65. Abstract

Lilenbaum R et al. A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. Proc ASCO 2012;Abstract 7506.

Quoix E et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378(9796):1079-88. Abstract

Temel JS et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363(8):733-42. Abstract

Weeks JC et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012;367:1616-25. Abstract

Frank C Detterbeck, MD

Detterbeck F, Rosenman J. Diagnosis and Treatment of Lung Cancer. WB Saunders, 2001.

Patchell RA et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500. Abstract

Jeffrey Bradley, MD
Aupérin A et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl N Med 1999;341(7):476-84. Abstract

De Ruysscher D et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24(7):1057-63. Abstract

Ghia A et al. Distribution of brain metastases in relation to the hippocampus: Implications for neurocognitive functional preservation. Int J Radiat Oncol Biol Phys 2007;68(4):971-7. Abstract

Jeremic B et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 1997;15(3):893-900. Abstract

Le Pechoux C et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): A randomised clinical trial. Lancet Oncol 2009;10(5):467-74. Abstract

Marsh JC et al. Intracranial metastatic disease spares the limbic circuit: A review of 697 metastatic lesions in 107 patients. Int J Radiat Oncol Biol Phys 2010;76(2):504-12. Abstract

Murray N et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11(2):336-44. Abstract

Slotman B et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357(7):664-72. Abstract

Takeda M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 2002;20:3054-60. Abstract

Turrisi AT et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:285-71. Abstract

New Agents and Research Strategies

Julie R Brahmer, MD

Brahmer JR et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). Proc ASCO 2012;Abstract 7509.

Chambers CA et al. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Ann Rev Immunol 2001;19:565-94. Abstract

Curran MA et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. PNAS 2010;107:4275. Abstract

Dong H et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8(8):793-800. Abstract

Gettinger S et al. Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc ESMO 2012. No abstract available

Greenwald RJ et al. The B7 family revisited. Annu Rev Immunol 2005;23:515. Abstract

Keir ME et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704. Abstract

Lynch TJ et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012:2046-54. Abstract

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64. Abstract

Pilon-Thomas S et al. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010;184:3442. Abstract

Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54. Abstract

Topalian SL et al. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24(2):207-12. Abstract

Tykodi SS et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. Proc ASCO 2012;Abstract 2510.

David R Spigel, MD

Acquaviva J et al. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 2012;11(12):2633-43. Abstract

Brahmer JR et al. A Phase 2 study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced NSCLC. World Conference on Lung Cancer 2011. No abstract available

Davies BR et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6(8):2209-19. Abstract

Janne PA et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14(1):38-47. Abstract

Yeh TC et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13(5):1576-83. Abstract

John Heymach, MD, PhD

Byers LA et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2012;19(1):279-90. Abstract

Frederick BA et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Therapeutics 2007;6:1683. Abstract

Kris MG. The Lung Cancer Mutation Consortium. 12th Annual Targeted Therapies in Lung Cancer 2012. No abstract available

Kuenen B et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG 1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010;2(23):1915-23. Abstract

Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. Abstract

Nikolova DA et al. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-Cadherin are novel biomarkers of cetuximab sensitivity. Cancer Research 2009;69(6):2461-70. Abstract

Ramalingam SS et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small cell lung cancer. J Clin Oncol 2012:3337-44. Abstract

Thomson S et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65(20):9455-62. Abstract

Wakelee HA et al. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). Proc ASCO 2010;Abstract 3017.

Yauch RL et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11(24 Pt 1):8686-98. Abstract

Rogerio C Lilenbaum, MD

Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25. Abstract